Physician profile
Amparo E Macariola
NPI 1932505401
$10,059.99
in general payments reported to CMS, 2019-2025
51 companies · $2,325 in 2025
The $2,325 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $596 · 2022: $2,371 · 2023: $2,390 · 2024: $2,378 · 2025: $2,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,597 · Education: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,597.01 |
| Education | $495.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $1,925.19 | 2021-2025 | |
| Abbvie INC. | $1,826.73 | 2021-2025 | |
| Ucb, INC. | $1,025.43 | 2021-2025 | Briviact, Nayzilam, Rystiggo |
| Harmony Biosciences LLC | $603.37 | 2022-2025 | Wakix |
| Lilly USA, LLC | $539.66 | 2021-2025 | Kisunla, Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $397.42 | 2022-2025 | Austedo Xr, Austedo, Ajovy |
| Pfizer INC. | $329.99 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $279.01 | 2022-2025 | |
| Sk Life Science, INC. | $214.38 | 2023-2024 | Xcopri |
| Alexion Pharmaceuticals, INC. | $206.59 | 2022-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $199.95 | 2021-2025 | Ingrezza |
| Celgene Corporation | $187.54 | 2024-2025 | Zeposia |
| Lundbeck LLC | $173.11 | 2021-2024 | Vyepti |
| Biohaven Pharmaceutical Holding Company Ltd. | $160.93 | 2022 | |
| Axsome Therapeutics, INC. | $160.58 | 2024-2025 | Sunosi |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amparo Macariola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.